2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2685

Anti-Peptidylarginine Deiminase 3/4 Cross-Reactive Antibodies Are Associated With Radiographic Interstitial Lung Disease In Rheumatoid Arthritis, An Effect Potentiated By Smoking
Abstract Number: 2547

Anti-Ribosomal P Antibody Has a Protective Role In The Development Of Chronic Kidney Disease In Patients With Lupus Nephritis
Abstract Number: 1600

Anti-Ribosomal P Protein Antibodies Exacerbate Long-Term Prognosis In Patients With Diffuse Neuropsychiatric/Neuropsychological Syndromes In Systemic Lupus Erythematous
Abstract Number: 632

Anti-Ribosomal-Phosphoprotein Autoantibodies Penetrate Into Neuronal Cells Via Neuron Growth Associated Protein (GAP43)
Abstract Number: 672

Anti-Th/To Antibodies In Various Systemic Rheumatic Diseases Screened By Anti-Rpp25 ELISA
Abstract Number: 1555

Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Abstract Number: 469

Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Abstract Number: 1473

Anti-Tumor Necrosis Factor α Therapy (Etanercept) Plus Methotrexate Lowers Serum Amyloid A Levels To a Greater Extent Than Triple Oral Disease Modifying Anti-Rheumatic Drug Therapy In Early Rheumatoid Arthritis Subjects
Abstract Number: 1532

Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis
Abstract Number: 1470

Anti-Tumour Necrosis Factor Alpha Therapy Reduces Platelet Reactivity and Is Associated With Improved Insulin Sensitivity In Patients With Inflammatory Arthritis
Abstract Number: 786

Antibodies Against Drp-4 and Macropain Subunit C2 As a Potential Marker Of Aosd
Abstract Number: 1777

Antibodies Against TIF1-Gamma In Cancer Associated Myositis May Precede Cancer Symptoms and Persist After Cancer Removal
Abstract Number: 1502

Antibodies To Anti-Type -3 Muscarinic Acetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With 4-Hydroxy-2-Noneal-Modified and 60-Kda Ro
Abstract Number: 2659

Antibodies To Citrullinated Enolase, Fibrinogen, and Vimentin Are Associated With Markers Of Endothelial Dysfunction In First-Degree Relatives Of Patients With Rheumatoid Arthritis: The Studies Of The Etiology Of Rheumatoid Arthritis
Abstract Number: 2430

Antibodies To Porphyromonas Gingivalis as An Etiological Clue To The Development Of Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].